Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

110.16 3.21 −2.83%
Market cap
$12.3B
P/E
212×
Fwd P/E
139×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

16.47% 14.79% 7.07% 8.08%
Piotroski F-Score
5 4 5 5
ROA
13.02% 11.71% 5.62% 6.41%
ROIC
19.01% 9.98% (1.71%) 1.01%
Return on Tangible Assets
28.22% 30.56% 16.67% 18.63%
Average Days of Receivables
34.29 28.66 18.54 33.79
Free Cash Flow per Share
1.58 1.37 1.15 1.01
Free Cash Flow
163.32 141.79 120.15 106.92
Other line items

Show all line items

Columns are period end dates